Showing results (131-140 of 219) with videos related to

Sort By:
Pageof 22
Coronary Artery Disease|April 1, 1994
The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. TIMI-III Thrombosis and Anticoagulation GroupR C Becker, R P Tracy, E G Bovill, et al.
Digestive Diseases and Sciences|March 1, 1985
Serum gamma-glutamyl transpeptidase and chronic alcoholism. Influence of alcohol ingestion and liver diseaseS N Moussavian, R C Becker, J L Piepmeyer, et al.
Hamostaseologie|December 7, 2007
Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapyR C Becker, S Oney, K C D Becker, et al.
Archives of Internal Medicine|April 14, 1997
Age-related trends (1986-1993) in the use of thrombolytic agents in patients with acute myocardial infarction. The Worcester Heart Attack StudyH Chandra, J Yarzebski, R J Goldberg, et al.
American Journal of Public Health|March 1, 1985
Physicians' attitudes and practices toward CPR training in family members of patients with coronary heart diseaseR J Goldberg, D DeCosimo, P St Louis, et al.
American Journal of Epidemiology|November 1, 1991
Diagnostic testing in acute myocardial infarction: does patient age influence utilization patterns? The Worcester Heart Attack StudyJ H Gurwitz, V Osganian, R J Goldberg, et al.
Archives of Internal Medicine|March 29, 2000
Payer status and the utilization of hospital resources in acute myocardial infarction: a report from the National Registry of Myocardial Infarction 2J G Canto, W J Rogers, W J French, et al.
Journal of the American College of Cardiology|June 17, 1998
Influence of payor on use of invasive cardiac procedures and patient outcome after myocardial infarction in the United States. Participants in the National Registry of Myocardial InfarctionM J Sada, W J French, D M Carlisle, et al.
Current Pharmaceutical Biotechnology|February 23, 2012
Antidote control of aptamer therapeutics: the road to a safer class of drug agentsK M Bompiani, R S Woodruff, R C Becker, et al.
Journal of Thrombosis and Thrombolysis|March 23, 2000
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralizationF A Spencer, S P Ball, Q Zhang, et al.
Pageof 22